Logo image of CLVS

CLOVIS ONCOLOGY INC (CLVS) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:CLVS - US1894641000 - Common Stock

0.0812 USD
0 (-5.58%)
Last: 12/20/2022, 9:19:57 PM
0.078 USD
0 (-3.94%)
After Hours: 12/20/2022, 9:19:57 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to CLVS. CLVS was compared to 531 industry peers in the Biotechnology industry. Both the profitability and financial health of CLVS have multiple concerns. CLVS is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year CLVS has reported negative net income.
In the past year CLVS has reported a negative cash flow from operations.
CLVS Yearly Net Income VS EBIT VS OCF VS FCFCLVS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 -100M -200M -300M -400M

1.2 Ratios

CLVS has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
CLVS Yearly ROA, ROE, ROICCLVS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 0 2K 4K 6K 8K

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for CLVS so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CLVS Yearly Profit, Operating, Gross MarginsCLVS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 0 -100K -200K -300K

More info and screens

0

2. Health

2.1 Basic Checks

CLVS does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, CLVS has more shares outstanding
Compared to 1 year ago, CLVS has a worse debt to assets ratio.
CLVS Yearly Shares OutstandingCLVS Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 20M 40M 60M 80M 100M
CLVS Yearly Total Debt VS Total AssetsCLVS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M 800M

2.2 Solvency

CLVS has an Altman-Z score of -16.18. This is a bad value and indicates that CLVS is not financially healthy and even has some risk of bankruptcy.
CLVS has a Altman-Z score of -16.18. This is amonst the worse of the industry: CLVS underperforms 87.79% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -16.18
ROIC/WACCN/A
WACC2.06%
CLVS Yearly LT Debt VS Equity VS FCFCLVS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 0 200M -200M 400M -400M 600M

2.3 Liquidity

CLVS has a Current Ratio of 0.14. This is a bad value and indicates that CLVS is not financially healthy enough and could expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 0.14, CLVS is doing worse than 96.24% of the companies in the same industry.
A Quick Ratio of 0.12 indicates that CLVS may have some problems paying its short term obligations.
The Quick ratio of CLVS (0.12) is worse than 96.40% of its industry peers.
Industry RankSector Rank
Current Ratio 0.14
Quick Ratio 0.12
CLVS Yearly Current Assets VS Current LiabilitesCLVS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 200M 400M 600M

More info and screens

4

3. Growth

3.1 Past

CLVS shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 36.04%, which is quite impressive.
The Revenue for CLVS has decreased by -14.78% in the past year. This is quite bad
The Revenue has been growing by 331.02% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.36%
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y331.02%
Sales Q2Q%-19.13%

3.2 Future

Based on estimates for the next years, CLVS will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.36% on average per year.
Based on estimates for the next years, CLVS will show a small growth in Revenue. The Revenue will grow by 4.17% on average per year.
EPS Next Y28.29%
EPS Next 2Y28.47%
EPS Next 3Y21.43%
EPS Next 5Y9.36%
Revenue Next Year-14%
Revenue Next 2Y1.79%
Revenue Next 3Y3.93%
Revenue Next 5Y4.17%

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
CLVS Yearly Revenue VS EstimatesCLVS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 50M 100M 150M
CLVS Yearly EPS VS EstimatesCLVS Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6 -8

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

CLVS reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for CLVS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CLVS Price Earnings VS Forward Price EarningsCLVS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CLVS Per share dataCLVS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2 -3

4.3 Compensation for Growth

CLVS's earnings are expected to grow with 21.43% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.47%
EPS Next 3Y21.43%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for CLVS!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CLOVIS ONCOLOGY INC

NASDAQ:CLVS (12/20/2022, 9:19:57 PM)

After market: 0.078 0 (-3.94%)

0.0812

0 (-5.58%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-09 2022-11-09/bmo
Earnings (Next)02-21 2023-02-21
Inst Owners0%
Inst Owner Change-98.86%
Ins Owners5.92%
Ins Owner Change0%
Market Cap11.77M
Revenue(TTM)133.02M
Net Income(TTM)-251.91M
Analysts42.86
Price Target2.04 (2412.32%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-5.55%
Min EPS beat(2)-18.6%
Max EPS beat(2)7.49%
EPS beat(4)3
Avg EPS beat(4)1.65%
Min EPS beat(4)-18.6%
Max EPS beat(4)17.44%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-12.2%
Min Revenue beat(2)-14.9%
Max Revenue beat(2)-9.51%
Revenue beat(4)0
Avg Revenue beat(4)-9.99%
Min Revenue beat(4)-14.9%
Max Revenue beat(4)-6.35%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)N/A
EPS NQ rev (1m)0%
EPS NQ rev (3m)N/A
EPS NY rev (1m)9.3%
EPS NY rev (3m)N/A
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-3.44%
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 0.09
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-0.8
Fwd EYN/A
FCF(TTM)-1.21
FCFYN/A
OCF(TTM)-1.21
OCFYN/A
SpS0.92
BVpS-2.88
TBVpS-3.71
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.38
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 3.45%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.14
Quick Ratio 0.12
Altman-Z -16.18
F-Score3
WACC2.06%
ROIC/WACCN/A
Cap/Depr(3y)116.85%
Cap/Depr(5y)382.21%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)36.04%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%30.36%
EPS Next Y28.29%
EPS Next 2Y28.47%
EPS Next 3Y21.43%
EPS Next 5Y9.36%
Revenue 1Y (TTM)-14.78%
Revenue growth 3Y15.96%
Revenue growth 5Y331.02%
Sales Q2Q%-19.13%
Revenue Next Year-14%
Revenue Next 2Y1.79%
Revenue Next 3Y3.93%
Revenue Next 5Y4.17%
EBIT growth 1Y11.13%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year18.44%
EBIT Next 3Y22.73%
EBIT Next 5Y8.67%
FCF growth 1Y36.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y34.2%
OCF growth 3YN/A
OCF growth 5YN/A

CLOVIS ONCOLOGY INC / CLVS FAQ

Can you provide the ChartMill fundamental rating for CLOVIS ONCOLOGY INC?

ChartMill assigns a fundamental rating of 1 / 10 to CLVS.


What is the valuation status for CLVS stock?

ChartMill assigns a valuation rating of 0 / 10 to CLOVIS ONCOLOGY INC (CLVS). This can be considered as Overvalued.


How profitable is CLOVIS ONCOLOGY INC (CLVS) stock?

CLOVIS ONCOLOGY INC (CLVS) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for CLVS stock?

The Earnings per Share (EPS) of CLOVIS ONCOLOGY INC (CLVS) is expected to grow by 28.29% in the next year.